Stefan Engst

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

F. Michael Yakes, Jason Chen, Jenny Tan et al. · Molecular Cancer Therapeutics · 2011 · 1.3K citations · Full text

Angiogenesis, Novel Met, Medicine +13

Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases

Fawn Qian, Stefan Engst, Peiwen Yu et al. · Cancer Research · 2009 · 336 citations

Tumor Cell Growth, Novel Inhibitor, Vegf Receptor 2 +16

Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition

Klaus P. Hoeflich, Mark Merchant, Christine Orr et al. · Cancer Research · 2011 · 242 citations · Full text

Chemoprevention Strategy, Apoptosis, Cell Death +19

Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)

Kenneth D. Rice, Naing Aay, Neel K. Anand et al. · ACS Medicinal Chemistry Letters · 2012 · 161 citations · Full text

Drug Target, Erk/map Kinase Cascade, Structural Insight +21

<i>In Vitro</i> and <i>In Vivo</i> Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer

Frauke Bentzien, Marcus Zuzow, Nathan Heald et al. · Thyroid · 2013 · 129 citations · Full text